Log in to search using one of your social media accounts:


GSE95771 AG221 and Ruxolitinib Treatment Effects on LSKs in IDH2-R140Q JAK2-V617F Transplant Recipients

Contributors : Anna S McKenney ; Barbara Spitzer ; Ross L LevineSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusTransplant recipients of IDH2-R140Q JAK2-V617F expressing bone marrow were treated with AG221 and ruxolitinib monotherapy, combined therapy, or vehicle. LSKs were sorted from terminal samples and sequenced with three WT controls.
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Mus musculus Source Type: research

Related Links:

More News: Genetics | Transplants